

Translational Lung Cancer Research is newly included by Scopus

Chao-Xiu (Melanie) He

Editorial Office, Translational Lung Cancer Research, AME Publishing Company, Guangzhou 510000, China

Correspondence to: Chao-Xiu (Melanie) He, Science Editor. Editorial Office, Translational Lung Cancer Research, AME Publishing Company, Room 11, 14/F, Chuangzhan Harbor Building, No. 82, Jiangnan Main Road, Haizhu District, Guangzhou 510000, China. Email: editor@tlcr.org.

Submitted Oct 31, 2015. Accepted for publication Nov 05, 2015.

doi: 10.3978/j.issn.2218-6751.2015.11.01

View this article at: <http://dx.doi.org/10.3978/j.issn.2218-6751.2015.11.01>

It is great to share with all the readers that *Translational Lung Cancer Research (TLCR)* has been accepted for inclusion in Scopus since October 2015. Scopus is one of the largest databases of peer-reviewed literature: scientific journals, books and conference proceedings in the world. This is another international recognition for *TLCR* after being indexed by PubMed.

Since first launched in March 2012, *TLCR*'s each step of development has been witnessed by its increasing number of readers worldwide. It is published quarterly in 2012, and bimonthly since February 2013. *TLCR* has been highlighted by MDLinx since December 2012, covered by Medscape since September 2013, and indexed by the Chemical Abstracts Service (CAS) Databases from May 2014, by PubMed/PubMed Central since December 2014, and by Scopus in October 2015 (*Figure 1*). Meanwhile, *TLCR* is accessible to a much wider range of readers via these different portals. More importantly, with more and more recognition from the international scientific community, the impact of *TLCR* is increasing as well (*Table 1*).

Though *TLCR* develops at a fast speed, there is no shortcut. *TLCR* persists to collaborate with the world-class experts throughout the world (*Figures 2,3*), with flexible novel formats to publish high-quality articles focusing on cutting-edge developments at the transition from preclinical to clinical research and thus closes the gap between “bench and bedside”, to meet multiple needs of global readers, and to pioneer the field of translational research of lung cancer.

Especially after being indexed by PubMed in December 2014, *TLCR* enters a new developing stage with a faster growing speed as compared with the development as before (1). Its publications not only come out regularly, but also focus on the up-to-date topics which are heatedly debated and well-received by readers, such as the three focused issues




Figure 1 The timeline of *TLCR*'s development. *TLCR*, *Translational Lung Cancer Research*.

published in 2015.

- Vol 4, No.2 (April, 2015), Focused Issue on Molecular Genetics of Lung Cancer, Guest Editor: Dr. Wendy A. Cooper, Royal Prince Alfred Hospital;
- Vol 4, No.4 (August, 2015), Focused Issue on Improving the Quality and Outcomes of Lung Cancer Care: An Interdisciplinary Approach, Guest Editor: Dr. Raymond U. Osarogiagbon, Baptist Cancer Center;
- Vol 4, No.5 (October, 2015), Focused Issue on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care, Guest Editor: Dr. Edward S. Kim, from Levine Cancer Institute.

Actually, the three focused issues along with former ones published in 2013 and 2014 have come out as previously planned, which shows that *TLCR* is apt to publish focused issues as scheduled with its collaborative efforts with Guest Editors, authors and the editorial team. And *TLCR* will continue to bring more high-quality focused issues to meet its global readers' demands (*Table 2*).

Along with the development of science and technology,

Table 1 Part of *TLCR*'s articles cited by peer influential journals (IF >3.00)

Cited articles of <i>TLCR</i>	Citing articles & published time	Citing journals	2013 IF of citing journals
Pliz LR, Manegold C, Schmid-Bindert G. Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? <i>Transl Lung Cancer Res</i> 2012;1:26-35.	Setting the bar for therapeutic trials in non-small-cell lung cancer: how low can we go? Published: May 10 2014.	<i>Journal of Clinical Oncology</i>	17.960
Teixidó C, Karachaliou N, Peg V, Gimenez-Capitan A, Rosell R. Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements. <i>Transl Lung Cancer Res</i> 2014;3:70-74.	Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Published: Apr 2015.	<i>Nature Reviews Clinical Oncology</i>	15.696
Bagai R, Ma PC. Combined treatment with MET inhibitors and other therapies in lung cancer. <i>Transl Lung Cancer Res</i> 2012;1:214-218.	Dramatic antitumor effects of the dual MET/ROS small-molecule inhibitor LY2801653 in non-small cell lung cancer. Published: Feb 2014.	<i>Cancer Research</i>	9.284
Padda S, Neal JW, Wakelee HA. MET inhibitors in combination with other therapies in non-small cell lung cancer. <i>Transl Lung Cancer Res</i> 2012;1:238-253.			
Menis J, Gijaj Levra M, Novello S. MET inhibition in lung cancer. <i>Transl Lung Cancer Res</i> 2013;2:23-39.			
Padda S, Neal JW, Wakelee HA. MET inhibitors in combination with other therapies in non-small cell lung cancer. <i>Transl Lung Cancer Res</i> 2012;1:238-253.	Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography. Published: Sep 15 2014.	<i>Clinical Cancer Research</i>	8.193
Butts CA. Anti-tumor immune response in early stage non small cell lung cancer (NSCLC): implications for adjuvant therapy. <i>Transl Lung Cancer Res</i> 2013;2:415-422.	Characterization of the cell of origin and propagation potential of the fibroblast growth factor 9-induced mouse model of lung adenocarcinoma. Published: Mar 2015.	<i>Journal of Pathology</i>	7.330
Kobayashi Y, Mitsudomi T. Management of ground-glass opacities: should all pulmonary lesions with ground-glass opacity be surgically resected? <i>Transl Lung Cancer Res</i> 2013;2:354-363.	Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growth. Published: Jan 2015.	<i>Annals of Oncology</i>	6.578

Table 1 (continued)

Table 1 (continued)

Cited articles of <i>TLCR</i>	Citing articles & published time	Citing journals	2013 IF of citing journals
Karachaliou N, Rosell R, Viteri S. The role of SOX2 in small cell lung cancer, lung adenocarcinoma and squamous cell carcinoma of the lung. <i>Transl Lung Cancer Res</i> 2013;2:172-179.	Identification and validation of long noncoding RNA biomarkers in human non-small-cell lung carcinomas. Published: Apr 2015.	<i>Journal of Thoracic Oncology</i>	5.800
Paumier A, Le Péchoux C. Post-operative radiation therapy. <i>Transl Lung Cancer Res</i> 2013;2:423-432.	Re-evaluation of the role of postoperative radiotherapy and the impact of radiation dose for non-small-cell lung cancer using the National Cancer Database. Published: Jan 2015.		
Weiss J. First line erlotinib for NSCLC patients not selected by EGFR mutation: keep carrying the TORCH or time to let the flame die? <i>Transl Lung Cancer Res</i> 2012;1:219-223.	Involvement of de novo synthesized palmitate and mitochondrial EGFR in EGF induced mitochondrial fusion of cancer cells. Published: Aug 1 2014.	<i>Cell Cycle</i>	5.006
Giordano FA, Welzel G, Abo-Madyan Y, Wenz F. Potential toxicities of prophylactic cranial irradiation. <i>Transl Lung Cancer Res</i> 2012;1:254-262.	Estimation of intracranial failure risk following hippocampal-sparing whole brain radiotherapy. Published: Oct 2013.	<i>Radiotherapy and Oncology</i>	4.857
Padda S, Neal JW, Wakelee HA. MET inhibitors in combination with other therapies in non-small cell lung cancer. <i>Transl Lung Cancer Res</i> 2012;1:238-253.	Crizotinib reduces the rate of dark adaptation in the rat retina independent of ALK inhibition. Published: Jan 2015.	<i>Toxicological Sciences</i>	4.478
Nel I, Jehn U, Gauler T, Hoffmann AC. Individual profiling of circulating tumor cell composition in patients with non-small cell lung cancer receiving platinum based treatment. <i>Transl Lung Cancer Res</i> 2014;3:100-106.	Predictive and prognostic value of circulating tumor cell detection in lung cancer: a clinician's perspective. Published: Feb 2015.	<i>Critical Reviews in Oncology and Hematology</i>	4.046
Crosbie PA, Shah R, Summers Y, Dive C, Blackhall F. Prognostic and predictive biomarkers in early stage NSCLC: CTCs and serum/plasma markers. <i>Transl Lung Cancer Res</i> 2013;2:382-397.	Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer. Published: Feb 12 2015.	<i>Journal of Translational Medicine</i>	3.991
Gu X, Ma C, Yuan D, Song Y. Circulating soluble intercellular adhesion molecule-1 in lung cancer: a systematic review. <i>Transl Lung Cancer Res</i> 2012;1:36-44.	Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy. Published: Mar 2013.	<i>Cancer Immunology and Immunotherapy</i>	3.943
Rosell R, Karachaliou N, Morales-Espinosa D, Costa C, Molina MA, Sansano I, Gasco A, Viteri S, Massuti B, Wei J, González Cao M, Martínez-Bueno A. Adaptive resistance to targeted therapies in cancer. <i>Transl Lung Cancer Res</i> 2013;2:152-159.	Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1. Published: Oct 2014.	<i>Journal of Pharmacology and Experimental Therapeutics</i>	3.855

Table 1 (continued)

Table 1 (continued)

Cited articles of <i>TLCR</i>	Citing articles & published time	Citing journals	2013 IF of citing journals
Teixido C, Karachaliou N, Peg V, Gimenez-Capitan A, Rosell R. Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements. <i>Transl Lung Cancer Res</i> 2014;3:70-74.	Detection of ALK rearrangements in malignant pleural effusion cell blocks from patients with advanced non-small cell lung cancer: a comparison of Ventana immunohistochemistry and fluorescence in situ hybridization. Published: Feb 2015.	<i>Cancer Cytopathology</i>	3.807
Teixido C, Karachaliou N, Peg V, Gimenez-Capitan A, Rosell R. Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements. <i>Transl Lung Cancer Res</i> 2014;3:70-74.	Future options for ALK-positive non-small cell lung cancer. Published: Mar 2015.	<i>Lung Cancer</i>	3.737
Prager GW, Poettler M, Unseld M, Zielinski CC. Angiogenesis in cancer: anti-VEGF escape mechanisms. <i>Transl Lung Cancer Res</i> 2012;1:14-25.	Normalization of tumor microenvironment by neom leaf glycoprotein potentiates effector T cell functions and therapeutically intervenes in the growth of mouse sarcoma. Published: Jun 2013.	<i>PLOS ONE</i>	3.534
Pirker R, Filipits M. Cetuximab in non-small-cell lung cancer. <i>Transl Lung Cancer Res</i> 2012;1:54-60.	EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer. Published: Nov 2013.	<i>Pharmacogenomics</i>	3.425
Giordano FA, Welzel G, Abo-Madyan Y, Wenz F. Potential toxicities of prophylactic cranial irradiation. <i>Transl Lung Cancer Res</i> 2012;1:254-262.	INTRAGO: intraoperative radiotherapy in glioblastoma multiforme – a phase I/II dose escalation study. Published: Dec 2014.	<i>BMC Cancer</i>	3.319
Metro G, Crinò L. Advances on EGFR mutation for lung cancer. <i>Transl Lung Cancer Res</i> 2012;1:5-13.	Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status. Published: Jan 2014.	<i>Clinical Lung Cancer</i>	3.220
Landi L, Cappuzzo F. Irreversible EGFR-TKIs: dreaming perfection. <i>Transl Lung Cancer Res</i> 2013;2:40-49.	Identification of new 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines as highly potent EGFR-TK inhibitors with Src-family activity. Published: Aug 1 2014.	<i>European Journal of Pharmaceutical Sciences</i>	3.005

TLCR, Translational Lung Cancer Research; IF, impact factor.




Figure 2 The geographical distribution of Editorial Board Members of *Translational Lung Cancer Research* (TLCR) (updated in April, 2015).




Figure 3 The geographical distribution of all authors of *Translational Lung Cancer Research* (TLCR) (updated in April, 2015).

Table 2 Future focused issues to be published on *Translational Lung Cancer Research (TLCR)*

Topic	Guest Editor	Department
Immunotherapy and Lung Cancer	María González Cao	Hospital Universitario Quiron Dexeus, Barcelona, Spain
Imaging and Radiotherapy in Lung Cancer	David Ball	Deputy Director of Radiation Oncology & Cancer Imaging, Chair of Lung Service, Peter MacCallum Cancer Centre, Melbourne, Australia
Small Cell Lung Cancer	Niki Karachaliou	Pangaea Biotech, USP Instituto Universitario Dexeus, Barcelona, Spain
Metabolic Reprogramming in Cancer as a Mechanism of Adaptive Resistance	Patrick Ma	Aerodigestive Oncology Translational Research THOR, Department of Solid Tumor Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
Liquid Biopsies in Lung Cancer	Miguel Angel Molina	Medical Oncology Service and Laboratory Hospital Universitario Quiron Dexeus, Barcelona, Spain
Lung Cancer Nursing	John White	Lead Macmillan Lung Cancer Nurse Specialist, St James's Hospital, Leeds Teaching Hospitals

Controversies on Lung Cancer: Pros and Cons (Section Chairs: Suresh Senan, Helmut H. Popper)

Exploring controversies in lung cancer using structured pro-con debates

Suresh Senan

PDF Pages: 475

HTML

Pros: long-term CT scan follow-up should be the standard of care in patients who are curatively treated for an early-stage non-small cell lung cancer

Waël C. Hanna

PDF Pages: 476-478

HTML

Cons: long-term CT-scan follow-up is not the standard of care in patients curatively treated for an early stage non-small cell lung cancer

Jan P. van Meerbeeck, Halil Sirimsi

PDF Pages: 479-483

HTML

Rebuttal from Dr Hanna

Waël C. Hanna

PDF Pages: 484

HTML

Rebuttal from Dr van Meerbeeck

Jan P. van Meerbeeck

PDF Pages: 485-486

HTML

Figure 4 Articles in *TLCR*'s new special section "Controversies on Lung Cancer: Pros and Cons". *TLCR*, *Translational Lung Cancer Research*.

more controversies emerge, and debates need evidences to support and resolve. Therefore, new special sections "Controversies on Lung Cancer" (*Figure 4*) and "Evidence-Based Medicine" (*Figure 5*) have been established in *TLCR* after sufficient preparations.

Moreover, we are happy to see that *TLCR* is growing together with its Editorial Board Members and authors. In May of this year, the study "EML4-ALK rearrangement in

blood platelets and outcome to crizotinib in non-small-cell lung cancer patients" of our Co-Editor-in-Chief Dr. Rafael Rosell and his team were presented at the annual congress of the American Society of Clinical Oncology (ASCO) in Chicago (*Figure 6*). On the 16th World Conference on Lung Cancer (WCLC) held in Denver in September, Honorary Editor-in-Chief, Editorial Board Member and Author of *TLCR*, have respectively won three out of the

Evidence-Based Medicine

PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis

Ze-Jun Zhou, Ping Zhan, Yong Song

PDF Pages: 203-208

HTML

Figure 5 Articles in *TLCR*'s new special section "Evidence-Based Medicine". *TLCR*, *Translational Lung Cancer Research*.



Figure 6 The study "EML4-ALK rearrangement in blood platelets and outcome to crizotinib in non-small-cell lung cancer patients" of our Co-Editor-in-Chief Dr. Rafael Rosell and his team were presented at the annual congress of the American Society of Clinical Oncology (ASCO) in Chicago.

four International Association for the Study of Lung Cancer (IASLC) distinguished awards (*Figure 7*). The IASLC Paul A. Bunn, JR. Scientific Award was given to Professor Yi-Long Wu from China, the Honorary Editor-in-Chief of *TLCR*; the Mary J. Matthews Pathology/Translational Research Award given to Professor Ming Sound Tsao from Canada, the Editorial Board Member of *TLCR*; and the Joseph W. Cullen Prevention/Early Detection Award given to Professor Jacek Jassem, Author of *TLCR* and Editorial Board Member of our sister journal *Annals of Translational Medicine (ATM)*.

Growing together with its editorial board members and authors, *TLCR* is encouraged by these experts who know it well, especially the prominent experts in the field of translational lung cancer research (*Figures 8-11*).



Figure 7 Honorary Editor-in-Chief, Editorial Board Member and Author of *TLCR*, have respectively won three out of the four IASLC distinguished awards. *TLCR*, *Translational Lung Cancer Research*; IASLC, International Association for the Study of Lung Cancer.



“ As Editor-in-Chief of *TLCR*, I am proud to say that the journal is very unique in its incorporation of several different formats and reader participation. Each issue focuses on cutting edge topics in lung cancer and presents the information with the most up to date technological and multimedia advances. Due to its modern and innovative format, *TLCR* is by far one of the most sought after journals by both physicians and researchers alike.”

Rafael Rosell, MD, Director, Cancer Biology & Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, 08916 Badalona, Barcelona, Spain

Figure 8 Encouraging words from Professor Rafael Rosell.



“ With their thoughtfully provided systematic reviews, this journal will emerge as a trust source of timely information on the complex emerging translational topics of the day for both clinicians and laboratory investigators... *TLCR* can also emerge as a leader in embracing the systematic collection of research information for subsequent independent re analysis to ensure more robust research results.”

James L. Mulshine, MD, FACP, Professor, Rush University; Acting Dean, Rush Graduate College; Vice President, Rush University, Chicago, Illinois, USA

Figure 9 Encouraging words from Professor James L. Mulshine.



“With its unique and innovative format, coupled with in-depth research articles, *TLCR* is one of the most pioneering journals for physicians and basic researchers of multiple disciplines (medical oncology, thoracic surgery, pathology, radiology, pulmonary medicine, cellular and molecular biology, and tumor genetics) working on lung cancer research.”

John D. Minna, M.D., Director of the Hamon Center for Therapeutic Oncology Research, The University of Texas, Southwestern Medical Center, Dallas, USA

Figure 10 Encouraging words from Professor John D. Minna.



“The Editors and the whole Editorial Team members are outstanding. The Editorial Board Members are well known lung cancer experts from all part of the world. The Editorial Team members are excellent in their performance and work very efficiently. They also support authors in their submission process whenever necessary. The publication processes is fast. The proofs are accurate. The printed and electronic versions of the manuscripts meet very high publication standards. The overall appearance of the journal is really excellent.”

Robert Pirker, MD, Professor of Medicine I, Department of Medicine I, Medical University of Vienna, Vienna, Austria

Figure 11 Encouraging words from Professor Robert Pirker.

Cite this article as: He CX. *Translational Lung Cancer Research* is newly included by Scopus. *Transl Lung Cancer Res* 2015;4(6):828-835. doi: 10.3978/j.issn.2218-6751.2015.11.01

In less than 2 months, about 30 distinguished experts in the field of lung cancer have given their testimonial words to *TLCR*. This is encouraging. We are honored to have their great contributions and encouragements on the road of *TLCR*'s growth. This is indispensable for the progresses that *TLCR* has made.

Embracing with all the encouragements and collaborative efforts with Editorial Board, Guest Editors, Authors, Reviewers and Readers worldwide, *TLCR* will continue to step forward and make contribution to the field of translational lung cancer research!

Acknowledgements

None.

Footnote

Conflicts of Interest: The author has no conflicts of interest to declare.

References

1. He MC, Li GS. Translational Lung Cancer Research is indexed by PubMed. *Transl Lung Cancer Res* 2015;4:1-4.